<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001361" GROUP_ID="SCHIZ" ID="412199082414431189" MERGED_FROM="" MODIFIED="2008-10-30 14:22:12 +0100" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;NIMH 1976 reference needed&lt;/p&gt;&lt;p&gt;Again I am not sure that all of andrew's comments were addressed in the text and unclear the implications of the criticism for our policy. Lorna, it would help if these type of comments were collated for the editors as we can learn from Andrew's experience. I am not clear from Seema's reply if the changes have been made in this review about to go on to the library or not.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Ready for submission 22/2/00&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 13:19:42 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0006" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-10-30 13:09:28 +0000" MODIFIED_BY="Samantha Roberts">
<TITLE>Depot haloperidol decanoate for schizophrenia</TITLE>
<CONTACT>
<PERSON ID="C0A9689A82E26AA20047FC71057E0AE8" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Marco</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Brasil</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>brasil@uninet.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Federal University of Rio de Janeiro</ORGANISATION>
<ADDRESS_1>R. Gustavo Sampaio 816</ADDRESS_1>
<ADDRESS_2>apt. 401 Leme</ADDRESS_2>
<CITY>Rio de Janeiro</CITY>
<ZIP>cep 22010.010</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55. 21. 25436625</PHONE_1>
<PHONE_2/>
<FAX_1>55.21.22443264</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-30 13:09:28 +0000" MODIFIED_BY="Samantha Roberts">
<PERSON ID="1185262582E26AA201DC7B3EC831FCE3" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Seema</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Quraishi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>quraishiseema@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute of Psychiatry</ORGANISATION>
<ADDRESS_1>103 Denmark Hill</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SE5 8AF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 020 3228 5086</PHONE_1>
<PHONE_2/>
<FAX_1>+44 020 3228 5129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1184F20682E26AA201DC7B3ED574C163" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>David</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Section - Consultant Psychiatrist</POSITION>
<EMAIL_1>a.david@iop.kcl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute of Psychiatry</ORGANISATION>
<ADDRESS_1>De Crespigny Park</ADDRESS_1>
<ADDRESS_2>BOX PO68</ADDRESS_2>
<CITY>London</CITY>
<ZIP>SE5 8AF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 171 919 3138</PHONE_1>
<PHONE_2/>
<FAX_1>+44 171 740 5301</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="C0A9689A82E26AA20047FC71057E0AE8" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Marco</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Brasil</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>brasil@uninet.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Federal University of Rio de Janeiro</ORGANISATION>
<ADDRESS_1>R. Gustavo Sampaio 816</ADDRESS_1>
<ADDRESS_2>apt. 401 Leme</ADDRESS_2>
<CITY>Rio de Janeiro</CITY>
<ZIP>cep 22010.010</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55. 21. 25436625</PHONE_1>
<PHONE_2/>
<FAX_1>55.21.22443264</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="C0AC356A82E26AA20047FC712424C60E" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Flávio</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Alheira</LAST_NAME>
<SUFFIX/>
<POSITION>MSc student</POSITION>
<EMAIL_1>flavioalheira@cremerj.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1>Rua Embaixador Carlos Taylor</ADDRESS_1>
<ADDRESS_2>95 Bloco 3 apto 403, Gavea</ADDRESS_2>
<CITY>Rio de Janeiro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>00 55 21 2274-8126</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-30 13:09:28 +0000" MODIFIED_BY="Samantha Roberts" NOTES="&lt;p&gt;Minor update: 25/08/00&lt;/p&gt;&lt;p&gt;Feedback added: 23/02/00&lt;/p&gt;&lt;p&gt;Response to feedback added: 23/02/00&lt;/p&gt;&lt;p&gt;Reformatted: 26/08/99&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 13:09:28 +0000" NOTES_MODIFIED_BY="Samantha Roberts">
<UP_TO_DATE>
<DATE DAY="25" MONTH="11" YEAR="1998"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="11" YEAR="1998"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="1999"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-30 10:55:08 +0000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS-R&amp;D Health Technology Assessment Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-30 11:34:07 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-30 11:26:12 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-30 11:26:12 +0000" MODIFIED_BY="[Empty name]">Depot haloperidol decanoate for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Synopsis pending.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The mainstay of treatment for schizophrenia is the antipsychotic group of drugs. These are usually given orally but compliance with medication given by this route may be difficult to quantify. Problems with treatment adherence are common. The development of depot injections in the 1960s gave rise to their extensive use as a means of long-term maintenance treatment. Haloperidol decanoate is one depot drug available in clinical practice .</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of haloperidol decanoate versus oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Relevant trials were identified by searching Biological Abstracts (1982-1998), Cochrane Library (Issue 2, 1998), Cochrane Schizophrenia Group's Register (June 1998), EMBASE (1980-1998), MEDLINE (1966-1998) and PsycLIT (1974-1998). References of all identified trials were also inspected for more studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All relevant randomised trials focusing on people with schizophrenia where haloperidol decanoate, oral anti-psychotics or other depot preparations were compared. Outcomes such as death, clinically significant change in global function, mental state, relapse, hospital admission, adverse effects and acceptability of treatment were sought.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Studies were reliably selected, quality rated and data extracted. For dichotomous data Mantel-Haenszel odds ratios (OR) with the 95% confidence intervals (CI) were estimated. Where possible, the number needed to treat statistic (NNT) was calculated. Analysis was by intention-to-treat. Normal continuous data were summated using the weighted mean difference (WMD). Scale data were presented only for those tools that had attained pre-specified levels of quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>In a haloperidol decanoate versus placebo comparison, two small studies reported that significantly fewer people on depot left early (OR 0.09 CI 0.03-0.21, NNT 2 CI 1-3) or experienced no important improvement in mental state (OR 0.04 CI 0.01-0.15). Zississ (1982) suggested that those taking haloperidol decanoate would need less additional antipsychotic medication (OR 0.14 Cl 0.04-0.55, NNT 2 CI 1-5).</P>
<P>Haloperidol decanoate was compared to oral haloperidol in a single trial that showed no differences in global impression, mental state or side effects (Zuardi 1983, n=22). Compliance with medication was not reported in this study. Eight trials compared haloperidol decanoate to other depot neuroleptics and again no differences were found for the outcomes of death, global impression, mental state, behaviour, or side effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Haloperidol decanoate may have a substantial effect in improving the symptoms and behaviour associated with schizophrenia in comparison to placebo, but data are remarkably sparse. </P>
<P>There are no discernible differences between the depot form of haloperidol and its oral equivalent. For those needing and willing to take the drug, the means of administration is then a matter of individual choice and clinical judgement. As there are no clear differences between haloperidol decanoate and other depots, the choice of depot medication could also be individually tailored and patient preference exercised.</P>
<P>Well-conducted and reported randomised trials are needed comparing haloperidol decanoate with other depots but the comparison of haloperidol decanoate to oral antipsychotics is a priority.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-30 11:34:07 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Schizophrenia affects about one in 10000 people per year, and the lifetime prevalence is approximately one percent (<LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>). It often runs a chronic course of acute exacerbation and partial remission. The mainstay of treatment for this illness is the antipsychotic group of drugs (<LINK REF="STD-Dencker-1980" TYPE="STUDY">Dencker 1980</LINK>). These are generally regarded as highly effective, especially in controlling such symptoms as hallucinations and fixed false beliefs (delusions) (<LINK REF="REF-Kane-1986" TYPE="REFERENCE">Kane 1986</LINK>). They also seem to reduce the risk of acute relapse. For example, over a decade ago a systematic review suggested that stopping antipsychotics caused 58% of people with serious mental illness to relapse. However, only 16% of those who were still on the drugs became acutely ill within a 1 year period (<LINK REF="REF-Davis-1986" TYPE="REFERENCE">Davis 1986</LINK>). Evidence also points to the fact that experiencing a relapse of schizophrenia lowers a person's level of social functioning and quality of life (<LINK REF="STD-Curson-1985" TYPE="STUDY">Curson 1985</LINK>). Relapse prevention also has enormous financial implications. For example, within the UK, a Department of Health burden of disease analysis in 1996 indicated that schizophrenia accounted for 5.4% of all National Heath Service in-patient expenditure, placing it behind only learning disability and stroke in magnitude (<LINK REF="REF-DoH-1996" TYPE="REFERENCE">DoH 1996</LINK>).</P>
<P>Anti-psychotic drugs are usually given orally (<LINK REF="REF-Aaes_x002d_Jorgenson-1985" TYPE="REFERENCE">Aaes-Jorgenson 1985</LINK>) but compliance with medication given by this route may be difficult to quantify. Problems with treatment adherence are common throughout medicine (<LINK REF="REF-Haynes-1979" TYPE="REFERENCE">Haynes 1979</LINK>). Those who suffer from schizophrenia, where treatments have uncomfortable side effects (<LINK REF="REF-Kane-1998" TYPE="REFERENCE">Kane 1998</LINK>) and the illness may cause cognitive impairment (<LINK REF="REF-David-1994" TYPE="REFERENCE">David 1994</LINK>) and erosion of insight, are especially prone to not take medication on a regular basis. The development of depot injections in the 1960s (<LINK REF="REF-Leff-1971" TYPE="REFERENCE">Leff 1971</LINK>) gave rise to extensive use of depots as a means of long-term maintenance treatment. Depots mainly consist of an ester of the active drug held in an oily suspension. This is injected intramuscularly and is slowly released. Depots may be given every 1 to 6 weeks. Individuals may be maintained in the community with regular injections administered by community psychiatric nurses, and sometimes in clinics set up specifically for this purpose (<LINK REF="REF-Barnes-1994" TYPE="REFERENCE">Barnes 1994</LINK>). </P>
<P>Haloperidol decanoate (HD) is one depot drug available in clinical practice (<LINK REF="STD-Rapp-1986" TYPE="STUDY">Rapp 1986</LINK>). It has been suggested to be as effective as its oral equivalent in controlling psychotic symptoms (<LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK>) and may have slightly less movement disorder (extrapyramidal) side effects when compared with other depot formulations (<LINK REF="REF-Reyntijens-1982" TYPE="REFERENCE">Reyntijens 1982</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of haloperidol decanoate versus placebo, oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia, in terms of clinical, social and economic outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-30 11:34:07 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-30 11:31:08 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials were considered. Where a trial was described as 'double-blind' and it was implied that the study was randomised, and where the demographic details of each group's participants were similar, trials were included. Quasi-randomised studies, such as those allocating by using alternate days of the week, were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia or other similar psychotic disorders, irrespective of mode of diagnosis, age, ethnicity and sex. Where a study described the participant group as suffering from 'serious mental illnesses' and did not give a particular diagnostic grouping, these trials were included. The exception to this rule was when the majority of those randomised clearly did not have a functional non-affective psychotic illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Haloperidol decanoate: any dose.<BR/>2. Oral anti-psychotic drugs: any dose.<BR/>3. Other depot antipsychotic drugs: any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-30 11:31:08 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes were grouped into immediate (0-5 weeks), short term (six weeks-five months), medium term (six months-one year) and longer term (more than 12 months).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-30 11:30:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clinical response<BR/>1.1 relapse</P>
<P>1.2 clinically significant response in global state - as defined by each of the studies</P>
<P>2. Service utilisation outcomes<BR/>2.1 hospital admission</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-30 11:31:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death, suicide or natural causes.</P>
<P>2. Leaving the study early.</P>
<P>3. Clinical response<BR/>3.1 clinically significant response in global state - as defined by each of the studies<BR/>3.2 average score/change in global state<BR/>3.3 clinically significant response on psychotic symptoms - as defined by each of the studies<BR/>3.4 average score/change on psychotic symptoms<BR/>3.5 clinically significant response on positive symptoms - as defined by each of the studies<BR/>3.6 average score/change in positive symptoms<BR/>3.7 clinically significant response on negative symptoms - as defined by each of the studies; and<BR/>3.8 average score/change in negative symptoms</P>
<P>4. Extrapyramidal side effects<BR/>4.1incidence of use of antiparkinson drug<BR/>4.2 clinically significant extrapyramidal side effects - as defined by each of the studies<BR/>4.3 average score/change in extrapyramidal side effects</P>
<P>5. Other adverse effects, general and specific</P>
<P>6. Service utilisation outcomes<BR/>6.1 days in hospital</P>
<P>7. Economic outcomes</P>
<P>8. Quality of life/satisfaction with care for either recipients of care or carers<BR/>8.1 significant change in quality of life/satisfaction - as defined by each of the studies<BR/>8.2 average score/change in quality of life/satisfaction.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-30 11:34:07 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-30 11:32:15 +0000" MODIFIED_BY="[Empty name]">
<P>Relevant randomised trials were identified by searching several electronic databases (Biological Abstracts, the Cochrane Library, the Cochrane Schizophrenia Group's Register of trials, EMBASE, MEDLINE, PsycLIT and SCISEARCH).</P>
<P>1. Biological Abstracts (January 1982 to June 1998 - current disc issue) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (HAL* near1 DECANOATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES))]</P>
<P>2 Cochrane Library (Issue 2, 1998) was searched using the Cochrane Schizophrenia Group's phrase for schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>and [(HAL* and DECANOATE) or ((DEPOT* or (LONG and ACTING) or (DELAY* and ACTION)) and (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES)) or (HALOPERIDOL* ME and DELAYED-ACTION-PREPARATIONS* ME))]</P>
<P>3 Cochrane Schizophrenia Group's Register (June 1998) was searched using the phrase:</P>
<P>and [(HAL* and DECANOATE) or ((DEPOT* or (LONG and ACTING) or (DELAY* and ACTION)) and (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES) or (#42=14 and #42=230) or #42=549)</P>
<P>4 EMBASE (January 1980 to June 1998 - current disc issue) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (HAL* near1 DECANOATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES)) or "HALOPERIDOL-DECANOATE"/ all subheadings]</P>
<P>5 MEDLINE (January 1966 to June 1998 - current disc issue) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>and [(HAL* near1 DECANOATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES)) or ("HALOPERIDOL"/ all subheadings and explode "DELAYED-ACTION-PREPARATIONS"/ all subheadings))]</P>
<P>6 PsycLIT (January 1974 to June 1998 - current disc issue) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (HAL* near1 DECANOATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (HALO* or HALDOL or SEREN* or SIGAPERIDOL or BROTOPON or EINALON or LINTON or PELUCES))]</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-30 11:31:41 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>The references of all identified trials were also inspected for more studies. Each of the included studies was sought as a citation on the SCISEARCH database. Reports of articles that had cited these studies were inspected in order to identify further trials.</P>
<P>2. Personal contact<BR/>The first author of each included study was contacted for information regarding unpublished trials. Also those companies producing depots were also contacted and requests for published and unpublished trials were made.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Study selection<BR/>The principal reviewer (SQ) inspected all reports of studies identified as above. A randomly selected sample of 10% of all reports was re-inspected by AD in order to ensure selection was reliable. Where disagreement occurred this was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. Once the full articles were obtained SQ and AD independently decided whether they met inclusion criteria. Where disagreement occurred this was resolved by discussion and when this was not possible, further information was sought. These trials were added to the list of those awaiting assessment pending acquisition of further information.</P>
<P>2. Assessment of methodological quality<BR/>Trials were allocated to three quality categories, as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1999" TYPE="REFERENCE">Mulrow 1999</LINK>) by each reviewer. When disputes arose as to which category a trial was allocated to, again, resolution was attempted by discussion. When this was not possible and further information was necessary to clarify into which category to allocate the trial, data were not entered and the trial was allocated to the list of those awaiting assessment. Only trials in Category A or B were included in the review. </P>
<P>3. Data collection<BR/>SQ and AD independently extracted data from selected trials. When disputes arose resolution was attempted by discussion. When this was not possible and further information was necessary to resolve the dilemma, data were not entered and this outcome of the trial was added to the list of those awaiting assessment. </P>
<P>4. Data synthesis<BR/>4.1 Incomplete data.<BR/>Where more than 30% of those randomised were lost to follow-up by 6 months, or 50% by beyond that time, data were felt to be too prone to bias to use and were not reported.</P>
<P>4.2 Dichotomous - yes/no - data.<BR/>4.2.1 Statistics: for binary outcomes, for example 'admitted' or 'not admitted', Mantel-Haenszel Odds Ratio with 95% confidence intervals was estimated. Where possible, the number needed to treat statistic (NNT) was also calculated.</P>
<P>4.2.2 Intention to treat: data were presented on a 'once-randomised-always-analyse' basis. Those lost to follow up were all assumed to have a negative outcome, with the exception of the outcome of death. For example, for the outcome of relapse, those who were lost to follow up all relapsed. A final sensitivity analysis was undertaken testing how prone the primary outcomes were to change when 'completed' data only were compared to the intention to treat analysis using the negative assumption. </P>
<P>4.3 Continuous - scale - data<BR/>4.3.1 Normal data: mental health continuous data are often not 'Normally' distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to all data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a continuous outcome starts from a finite number (such as zero), the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Data that do not meet the second standard were not entered into the RevMan calculator (which assumes a Normal distribution). However, data not meeting these standards can be reported in the 'Other data types' of the results section if they had been analysed with appropriate non-parametric tests.</P>
<P>If continuous data were recording change, where the finite parameters of measure were unclear then the data were not used.</P>
<P>4.3.2 Rating scales: a wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are ad hoc. For outcome instruments some minimum standards have to be set. They could be that: (a) the psychometric properties of the instrument should have been described in a peer-reviewed journal; (b) the instrument was not written or modified by one of the trialists; (c) the instrument should either be: (i) a self-report, or (ii) completed by an independent rater or relative (not the therapist); and (d) the instrument should be a global assessment of an area of functioning). <BR/>
<BR/>5. Heterogeneity<BR/>As well as inspecting the graphical presentations, differences between the results of each included trial were checked using a test of heterogeneity. This is automatically calculated by RevMan. If heterogeneity is present the reviewers undertake a sensitivity analysis to the presence or absence of these data. All data from studies that have been selected are presented. </P>
<P>6. Tables and figures<BR/>Where possible data were entered into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for haloperidol decanoate.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Please see Included and Excluded studies tables.</P>
<P>1. Excluded studies<BR/>Studies were most frequently excluded because they were not randomised or, if they were controlled clinical trials, because HD was not used as an intervention. Where relevant trials provided no usable data (<LINK REF="STD-Baastrup-1993" TYPE="STUDY">Baastrup 1993</LINK>, <LINK REF="STD-Cookson-1991" TYPE="STUDY">Cookson 1991</LINK>, <LINK REF="STD-Dencker-1994" TYPE="STUDY">Dencker 1994</LINK>, <LINK REF="STD-Rapp-1986" TYPE="STUDY">Rapp 1986</LINK>, <LINK REF="STD-Ushakov-1990" TYPE="STUDY">Ushakov 1990</LINK>, <LINK REF="STD-Wiles-1990" TYPE="STUDY">Wiles 1990</LINK>) authors were contacted but no reply has been received. <LINK REF="STD-Wiles-1990" TYPE="STUDY">Wiles 1990</LINK> was also excluded because, although randomised, it did not measure clinical outcomes but primarily physiological measures such as plasma levels. </P>
<P>2. Included studies<BR/>2.1 Duration<BR/>This ranged from four months to one year (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>). </P>
<P>2.2 Participants<BR/>The participant group was reasonably homogeneous with most studies including those with a diagnosis of schizophrenia or similar psychotic disorder, people of both sexes, with ages ranging from 18-71 years old. Although people with recent onset of illness were included in some studies, participants frequently had long histories of illness. </P>
<P>2.3 Setting<BR/>The trials were both community and hospital based. In one study the trialists gave participants the first two injections whilst in hospital and continued treatment in the community thereafter (<LINK REF="STD-Wistedt-1991" TYPE="STUDY">Wistedt 1991</LINK>). <LINK REF="STD-Eklund-1991" TYPE="STUDY">Eklund 1991</LINK> included people from both hospital and community. <LINK REF="STD-Kissling-1985" TYPE="STUDY">Kissling 1985</LINK> failed to mention the setting used. </P>
<P>2.4 Interventions<BR/>Two trials compared HD with placebo (<LINK REF="STD-Eklund-1991" TYPE="STUDY">Eklund 1991</LINK>, <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK>), one with its oral equivalent (<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK>) and the remaining eight with other depot formulations. </P>
<P>2.5 Outcome measures<BR/>Apart from leaving the study early and use of additional medication most outcomes, even those later dichotomised, were measured on rating scales which are listed below. </P>
<P>Many trials presented findings in graphs or by p-values alone. Graphical presentation made it impossible to acquire data for synthesis. 'P' values were commonly used as a measure of association between intervention and outcomes instead of showing the strength of the association. With the exception of Drs McKane (<LINK REF="STD-McKane-1987" TYPE="STUDY">McKane 1987</LINK>) and Zuardi (<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK>), requests for further information from authors have, so far, failed.</P>
<P>2.5.1 Global functioning<BR/>Clinical Global Impression - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery.</P>
<P>2.5.2 Mental state <BR/>Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 16 items, and each item can be defined on a seven-point scale varying from 'not present' (zero) to 'extremely severe' (seven). Scoring is from 24-168.</P>
<P>Comprehensive Psychopathological Rating Scale - CPRS (<LINK REF="REF-Asberg-1978" TYPE="REFERENCE">Asberg 1978</LINK>) <BR/>A four-point scale is used by the participant to rate 40 items, and 25 items are rated using the same scale. Global rating of the illness is an additional item also rated using this scale. Assumed reliability of the rating is scored as zero (very poor), one (fair), two (good) or three (very good).</P>
<P>Krawiecka Scale (<LINK REF="REF-Krawiecka-1977" TYPE="REFERENCE">Krawiecka 1977</LINK>)<BR/>This mental state scale encompasses both positive and negative symptoms of schizophrenia. It is used to evaluate the mental state and behaviour in chronic psychotic people with higher scores indicating greater severity. It is also known as the Manchester Scale. </P>
<P>2.5.3 Behaviour<BR/>Nurses Observational Scale of Inpatients Evaluation - NOSIE (<LINK REF="REF-Honigfeld-1962" TYPE="REFERENCE">Honigfeld 1962</LINK>).<BR/>An 80-item scale in which items are rated from 0-4. Zero means never present and four continually present. Ratings are taken from behaviour over the previous three days. The seven headings are: social competence, social interest, personal neatness, co-operation, irritability, manifest psychosis and psychotic depression. Scoring ranges from 0-320.</P>
<P>2.5.4 Side-Effects<BR/>Abnormal Involuntary Movement Side Effects Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is a twelve-item scale designed to record the occurrence of dyskinetic movements. Ten items of this scale have been used to assess tardive dyskinesia, a long-term drug-induced movement disorder. A five-point scoring system (from zero: none to four: severe) has been used to rate each of the ten items. Using this scale in short-term treatment may be helpful in assessing some short-term abnormal movement disorders. A low score indicates low levels of dyskinetic movements.</P>
<P>Dosage Record and Treatment Emergent Symptoms Scale - DOTES (NIMH 1976)<BR/>This side effect tool seems less of a scale, where the degree and severity of a symptom is recorded, and more of a checklist. The DOTES<BR/>seems to record the presence or absence of a list of side effects.</P>
<P>Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>Simpson and Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>) <BR/>A standard physical examination which measures parkinsonism. This scale comprises of a 10-item rating scale, each item rated on a five point scale with zero meaning the complete absence of condition and four meaning the presence of condition in extreme. The total score is obtained by adding the items and dividing by 10. </P>
<P>UKU Side Effects Rating Scale - UKU-SERS (<LINK REF="REF-Lingjerde-1987" TYPE="REFERENCE">Lingjerde 1987</LINK>).<BR/>The UKU rates four major topics: psychological side effects (10 items), neurological side effects (eight items), autonomic side effects (11 items) and other side effects (19 items). Each item is defined by means of a four-point scale where zero means not or doubtfully present. Scoring range is 0-144.</P>
<P>2.6 Missing outcomes<BR/>Not one study evaluated hospital/service outcomes, satisfaction with care and economic outcomes.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>Only <LINK REF="STD-Kissling-1985" TYPE="STUDY">Kissling 1985</LINK> specified the process by which allocation to the intervention group was undertaken (coin-throwing) but did not specify whether this allocation was impossible for the clinician or participant to influence. As poor reporting of randomisation has consistently been associated with an overestimate of effect (<LINK REF="REF-Schulz-1994" TYPE="REFERENCE">Schulz 1994</LINK>) all allocation concealment has been rated as 'unclear' or quality 'B'. The results in these trials are likely to be a 30-40% overestimate of effect (<LINK REF="REF-Schulz-1994" TYPE="REFERENCE">Schulz 1994</LINK>, <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). </P>
<P>2. Blinding at outcome<BR/>All studies described themselves as 'double blind' but there is no report of this being tested. The two questions, one to the participant - "what do you think you have been given?" and one to the rater - "what drug do you think this person was allocated?" would have clarified the situation. Failure to test double blinding may cast doubt on the quality of trial data. Scale data, as was often measured in the included studies, may be prone to bias when unblinding has taken place. </P>
<P>3. Follow-up<BR/>Overall, losses to follow up were well described.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>Three hundred and seven citations were found using the search strategy. Thirty-two citations were related to haloperidol decanoate but only eleven referred to controlled clinical trials (all published in journals). A small number (four) of non-English papers are still awaiting assessment due to delays in translation.</P>
<P>2. COMPARISON 1. HALOPERIDOL DECANOATE versus PLACEBO</P>
<P>2.1 Not completing the study<BR/>Both studies (<LINK REF="STD-Eklund-1991" TYPE="STUDY">Eklund 1991</LINK>, <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK>) reported that significantly fewer people on haloperidol decanoate left the study early (n=74, OR 0.09 CI 0.03-0.21, NNT 2 CI 1-3). <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK> was a small trial (n=32) lasting only four months and participants were actively withdrawn by the trialists if felt not to be responding. Despite being withdrawn from treatment protocol, data were collected on other outcomes. The <LINK REF="STD-Eklund-1991" TYPE="STUDY">Eklund 1991</LINK> study was one year long and those not completing represent true attrition. As data were not collected for the considerable proportion that left early this trial does not add further to the review. </P>
<P>2.2 Global Impression<BR/>Data from one small trial (<LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK>) suggested that those taking haloperidol decanoate would need less of other types of antipsychotic medication (n=32, OR 0.14 Cl 0.04-0.55, NNT 2 CI 1-5).</P>
<P>2.3 Mental state<BR/>As <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK> withdrew people from the study if treatment was felt to be ineffective, these data can be used as a proxy for no clinically important improvement in mental state (OR 0.04 CI 0.01-0.15). <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK> also used a continuous scale for mental state (BPRS) but unfortunately presented total scores for each group without means or standard deviations. <BR/>
<BR/>2.4 Side effects<BR/>
<LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK> reported significantly more people in the placebo group experienced blurred vision as a side effect than in the haloperidol decanoate group (OR 0.17 CI 0.03-0.89). This trial also found no difference between groups for the outcome of tremor (OR 1.0 CI 0.24-4.09).</P>
<P>3. COMPARISON 2. HALOPERIDOL DECANOATE versus ORAL ANTIPSYCHOTICS</P>
<P>Only one small study (<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK>, n=22) compared haloperidol decanoate an oral antipsychotic, in this case, oral haloperidol.</P>
<P>3.1 Global impression<BR/>
<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK> reported no difference between those allocated to haloperidol decanoate and those taking oral medication (OR 0.61 CI 0.09-4.28) for the outcome of 'no improvement at four months'.</P>
<P>3.2 Mental state<BR/>BPRS scores were also not different between groups.</P>
<P>3.3 Side effects<BR/>
<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK> reported no significant differences in numbers needing anticholinergic drugs (OR 3.21 Cl 0.39-26.67). This trial also used the Bordeleau Scale to rate extrapyramidal side effects. The skewed data is presented in 'Other data tables' and is not different for those taking haloperidol decanoate and the group allocated to oral drug.</P>
<P>4. COMPARISON 3. HALOPERIDOL DECANOATE versus OTHER DEPOT NEUROLEPTICS</P>
<P>There were eight eligible trials.</P>
<P>4.1 Death<BR/>Two deaths occurred in two of the studies, both in control groups (<LINK REF="STD-McKane-1987" TYPE="STUDY">McKane 1987</LINK>, <LINK REF="STD-Wistedt-1991" TYPE="STUDY">Wistedt 1991</LINK>). The result was not statistically significant (n=97, OR 0.15 CI 0.01-2.37).</P>
<P>4.2 Global impression<BR/>There was no difference in the numbers of people needing additional antipsychotic medication across groups (n=113, OR 0.63 CI 0.17-2.3). Direct measure of global state at the end of the studies also showed no discernible difference on the Clinical Global Impression (CGI - <LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>). The skewed CGI data reported in <LINK REF="STD-Wistedt-1991" TYPE="STUDY">Wistedt 1991</LINK> was also equivocal.</P>
<P>4.3 Mental state<BR/>Seven studies reported 'relapse' as an outcome and no difference was found between the haloperidol decanoate group and those allocated to other depots (n=317, OR 1.25 Cl 0.65-2.42). The two studies reporting un-skewed BPRS endpoint scores (<LINK REF="STD-Bechelli-1985" TYPE="STUDY">Bechelli 1985</LINK>, <LINK REF="STD-Chouinard-1984" TYPE="STUDY">Chouinard 1984</LINK>) support this equivocal finding. Skewed data is not formally analysed but is supportive of the overall impression that no difference is apparent in the mental state of those who take haloperidol decanoate and people given other depots.</P>
<P>4.4 Behaviour<BR/>Eight trials in which 371 people had been randomised to haloperidol decanoate or other depots had, in total, 18% attrition. There is no significant difference between groups (OR 0.92 CI 0.52-1.6). Skewed endpoint data from the Wing Ward Behaviour Scale seemed to support the finding that there was no clear behavioural differences between those taking haloperidol decanoate and other depots.</P>
<P>4.5 Side effects<BR/>The instance of dyskinetic movements was the same across groups in the two small studies reporting this effect (<LINK REF="STD-Bechelli-1985" TYPE="STUDY">Bechelli 1985</LINK>, <LINK REF="STD-Wistedt-1991" TYPE="STUDY">Wistedt 1991</LINK>). Both reported no significant differences in the number of people who suffered from dyskinesia in either the haloperidol decanoate or the control group (n=105, OR 1.85 CI 0.61-5.63). <LINK REF="STD-Bechelli-1985" TYPE="STUDY">Bechelli 1985</LINK> reported no difference in tremor between the two groups (n=41, OR 0.75 CI 0.2-2.75) and <LINK REF="STD-Wistedt-1991" TYPE="STUDY">Wistedt 1991</LINK>, using a questionnaire to identify those with significant adverse effects, also found no difference. Some skewed data generally supports these findings.</P>
<P>Five studies reported there was no difference in the number of people requiring anticholinergic medication, irrespective of the depot treatment they received (n=257, OR 0.8 CI 0.43-1.47).</P>
<P>5. Missing outcomes<BR/>No study directly reported hospital and service outcomes or commented on participants' overall satisfaction during or after the trial. Economic outcomes were not assessed by any of the included studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Generalisability<BR/>Most trial participants had an operationalised diagnosis of schizophrenia (DSM III, RDC, Feighner's criteria) although <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> did not specify if diagnostic criteria were used. The varied criteria suggest that the diagnoses could be heterogeneous, as is the situation in routine practice. On average the duration of illness was long but ranged from 0-31 years. </P>
<P>2. COMPARISON 1. HALOPERIDOL DECANOATE versus PLACEBO</P>
<P>About 40% of the people in the two studies (<LINK REF="STD-Eklund-1991" TYPE="STUDY">Eklund 1991</LINK>, <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK>) left the study early, the maximum duration of either study being one year. However, in the <LINK REF="STD-Zissis-1982" TYPE="STUDY">Zissis 1982</LINK> study those whose illness had not responded were withdrawn by the trialists so a too rigorous trial protocol cannot be held solely responsible for the loss. In fact, it is this study that provides the limited, but best, trial-based evidence regarding the absolute effectiveness of haloperidol decanoate for the outcome of 'general response' (NNT 1.23 CI 1-2). This trial-base is, however, very limited but it is probable that clinicians' and patients' experience of haloperidol, and its depot, is so great that the reasonable doubt does not exist to allow a good large trial to be undertaken. </P>
<P>The result for 'general response' fits with the finding that people taking haloperidol decanoate need less additional medication than those on placebo group (NNT 2 CI 1-5). It is, however, surprising that significantly more of those allocated placebo experienced blurred vision than those taking haloperidol decanoate and that tremor occurred with equal frequency in both groups. </P>
<P>As is usual for those systematically reviewing trial literature, continuous measures add little to the information provided by simple clinically meaningful outcome such as 'improved' or 'not improved'. </P>
<P>3. COMPARISON 2. HALOPERIDOL DECANOATE versus ORAL ANTIPSYCHOTICS</P>
<P>
<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK>, a single trial with 22 participants, compared haloperidol decanoate with oral haloperidol. The author failed to report how many people left the study early or relapsed during the trial. This is unfortunate as comparative compliance is currently a major concern in modern-day treatments of schizophrenia. Observing the effect of oral and depot antipsychotic drugs in terms of clinical efficacy, side effects and social implications has a wide role to play in constructing a sound basis for the choice the clinician makes as to what medication to prescribe. The main benefit of depot formulations is that covert non-compliance is eliminated and, if relapse does occur under these circumstances, non-compliance can be ruled out. Of course, generalising any findings of any study to routine care is problematic as those entering trials are usually more compliant than is commonplace in day-to-day practice. This issue becomes academic when there are no results to generalise.</P>
<P>With such a small study it is not surprising that there was little difference between those allocated to the depot and the oral haloperidol. The power of such a study to highlight a real effect is minimal. The non-significant finding for the outcome of 'no improvement at four months' (OR 0.61 CI 0.09-4.28) could mask a real, and important effect in favour of haloperidol decanoate. The same argument applies to the mental state rating and recording of side effects or the need for anticholinergic medication. </P>
<P>For this comparison clinical doubt may be great enough to allow a well designed trial to be instigated.</P>
<P>4. COMPARISON 3. HALOPERIDOL DECANOATE versus OTHER DEPOT NEUROLEPTICS</P>
<P>That two deaths occurred in two small trials (n=97) over a period of about a year serves to highlight the morbidity and mortality associated with schizophrenia. Much larger studies would be needed to find a real difference between haloperidol decanoate and other depot antipsychotics if one really exists. </P>
<P>All other findings relating to the global impression of effect, specific mental state measures, behaviour, and side effects are equivocal. This is not too surprising for small studies where the comparison is perhaps driven by the pharmaceutical industry whose need is to provide data on clinical effectiveness on new agents. Any differences would probably be subtle and such small studies could not highlight these. </P>
<P>That eight randomised trials, with a total of 371 very ill participants, lost only 18% of people over a relatively long period of time shows that such low attrition is possible although generalisation to a wider population must be undertaken with caution. </P>
<P>5. Sensitivity analyses<BR/>Undertaking an analysis based solely on study 'completers' as opposed to all those randomised did not make any substantive difference to the results. Intention to treat analyses are presented.</P>
<P>6. Missing outcomes<BR/>No study directly reported hospital and service outcomes or commented on participants' overall satisfaction during or after the trial. Economic outcomes were not assessed by any of the included studies.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. Those with schizophrenia<BR/>HD may well have a substantial effect in improving the symptoms and behaviour associated with schizophrenia in comparison to placebo - but data are remarkably sparse. </P>
<P>There are no discernible differences between the depot form of haloperidol and its oral equivalent. For those needing and willing to take the drug, the means of administration is then a matter of individual choice. </P>
<P>As there are no clear differences between HD and other depots, the choice of depot medication could also be individually tailored and patient preference exercised.</P>
<P>2. Managers or policy makers<BR/>Data relating to service utilisation, satisfaction with care and economic outcomes were not reported. </P>
<P>3. Clinicians<BR/>People with schizophrenia can be assured that depot haloperidol does seem to be more effective than placebo.</P>
<P>The best data in this review relate to the comparison of HD and other depot preparations. There is nothing to choose between depots for outcomes of mental state, behaviour, side effects and compliance/concordance. The choice of which depot to use can therefore be based on clinical judgement and the preferences of the recipients of care and their carers. </P>
<P>Should a person wish to take oral haloperidol and not the depot form, what very limited data there are would suggest that this is a reasonable plan, assuming all other factors are equal.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>If the recommendations of the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>) had been anticipated by trialists much more data would have been available to inform practice. Clear descriptions of randomisation would have reassured the user of the trials that selection bias had been minimised. Well described and tested blinding could have encouraged confidence in the control of performance and detection bias. It is also important to know how many, and from which groups, people were withdrawn, in order to evaluate exclusion bias.</P>
<P>It would have been helpful if authors had presented data in a useful manner which reflects association between intervention and outcome, for example, relative risk, odds-ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results as they are easier to interpret. If p-values are used, the exact value should be reported.</P>
<P>2. Specific<BR/>This review highlights the need for good controlled clinical trials to address the effectiveness and clinical outcome of using haloperidol decanoate for those with schizophrenia. More research is particularly required in the case of haloperidol decanoate compared with oral antipsychotics. Data were poor in this group as only one small trial could be included (<LINK REF="STD-Zuardi-1983" TYPE="STUDY">Zuardi 1983</LINK>). This study was based in hospital. As one of the reasons for the use of haloperidol decanoate is to increase compliance, it would seem important for similar, but larger, trials to be based in the community where supervision may be less rigorous. Future studies should report service utilisation data, as well as satisfaction with care and economic outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Leanne Roberts for her help and support. We would also like to thank Dr Chiara Nosarti, Dr Cookson, Dr McCreadie and Dr Zuardi for their assistance.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Seema Quraishi - prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report.</P>
<P>Anthony David - acquired funding, helped prepare protocol, select studies, extract data, and produce the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Cochrane Schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-30 13:19:42 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-30 13:19:42 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bechelli-1985" NAME="Bechelli 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechelli LPC, Lecco MC, Pontes MC</AU>
<TI>A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>662-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1984" NAME="Chouinard 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J</AU>
<TI>A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>108-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Campbell W</AU>
<TI>A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cookson-1986" NAME="Cookson 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cookson JC, Kennedy NM, Gribbon D</AU>
<TI>Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>Suppl 1</VL>
<PG>41-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eberhard-1986" NAME="Eberhard 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eberhard G, Hellbom E</AU>
<TI>Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1986</YR>
<VL>74</VL>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eberhard G</AU>
<TI>Depot antipsychotics in schizophrenic patients: a comparison between haloperidol decanoate and flupenthixol decanaote</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>Suppl 1</VL>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eklund-1991" NAME="Eklund 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eklund K, Forsman A</AU>
<TI>Minimal effective dose and relapse - double blind trial: haloperidol decanoate versus placebo</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>Suppl 2</NO>
<PG>7-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kissling-1985" NAME="Kissling 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kissling W, Moller HJ, Walter K, Wittmann B, Krueger R, Trenk D</AU>
<TI>Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1985</YR>
<VL>18</VL>
<PG>240-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKane-1987" NAME="McKane 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCreadie RG, McKane JP, Robinson ADT, Wiles DH, Stirling GS</AU>
<TI>Depot neuroleptics as maintenance therapy in chronic schizophrenic in-patients - Abstract</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>Suppl 1</VL>
<PG>13-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS</AU>
<TI>Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>151</VL>
<PG>333-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistedt-1984" NAME="Wistedt 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B, Persson T, Hellbom E</AU>
<TI>A clinical double blind comparison between haloperidol decanoate and fluphenazine decanoate</TI>
<SO>Current Therapeutic Research</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>5</NO>
<PG>804-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B</AU>
<TI>A comparison trial of haloperidol decanoate and fluphenazine decanaote in chronic schizophrenic patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>Suppl 1</VL>
<PG>15-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistedt-1991" NAME="Wistedt 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Kosiken T, Wistedt B, Thelander S</AU>
<TI>Zuclopenthixol decanoate vs haloperidol decanoate: A double-blind comparative trial</TI>
<SO>Proceedings of the 5th World Congress of Biological Psychiatry; Florence, Italy,</SO>
<YR>June 9-14, 1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Molbjerg C</AU>
<TI>Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1991</YR>
<VL>84</VL>
<PG>14-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zissis-1982" NAME="Zissis 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zissis NP, Psaras M, Lyketsos G</AU>
<TI>Haloperidol decanoate, a new long acting antipsychotic in chronic schizophrenics: double-blind comparison with placebo</TI>
<SO>Current Therapeutic Research</SO>
<YR>1982</YR>
<VL>31</VL>
<NO>4</NO>
<PG>650-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zuardi-1983" NAME="Zuardi 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuardi AW, Giampietro AC, Grassi ER, Matos Lima AA, Buoncompagno EM, Ribeiro Dos Santos CH, Bredariol MM, Fiestrino A, Oliveria MAS, Moura DSP, Karniol IG</AU>
<TI>Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>2</NO>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Angus-1997" NAME="Angus 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angus S, Sugars J, Boltezar R, Koskewich S, Scheider N M</AU>
<TI>A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>2</NO>
<PG>88-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baastrup-1993" NAME="Baastrup 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-Andersen K, Lindholm H, Lybeck I, Morawski R, Nummi K, Silfverhjelm H, Vartainen H, Wiesel FA, Aarvold A</AU>
<TI>A controlled Nordic mulitcentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in treatment of acute psychosis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<PG>48-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bucci-1985" NAME="Bucci 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bucci L, Marini S</AU>
<TI>Haloperidol decanoate in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1091-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cookson-1991" NAME="Cookson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cookson JC</AU>
<TI>C. Side effects during long term treatment with depot antipsychotic medication</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>Suppl 2</NO>
<PG>24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curson-1985" NAME="Curson 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC</AU>
<TI>Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the medical research council fluphenazine/placebo trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>146</VL>
<PG>464-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deberdt-1980" NAME="Deberdt 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deberdt R, Elens P, Berghmans W, Heykants J, Woestnborghs R, Dreisens F, Reyntjens A, van Wijngaarden I</AU>
<TI>Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1980</YR>
<VL>62</VL>
<PG>356-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dencker-1980" NAME="Dencker 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Lepp M, Malm U</AU>
<TI>Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1980</YR>
<VL>279</VL>
<PG>10-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dencker-1994" NAME="Dencker 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Gios I, Martensson E, Norden T, Nyberg G, Persson R, Roman G, Stockman O, Svard KO</AU>
<TI>A long term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanaote in schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>114</VL>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernando-1984" NAME="Fernando 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernando J, Krishna Raju R, Jones GG, Stanley RO</AU>
<TI>The use of depot neuroleptic haloperidol decanoate</TI>
<SO>Acta Psychiatrica Scandanavica</SO>
<YR>1984</YR>
<VL>69</VL>
<PG>175-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gianelli-1990" NAME="Gianelli 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gianelli A, Rabboni M, Zarattini F</AU>
<TO>Profili clinici di azione, indicazinoi preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1990</YR>
<VL>25</VL>
<PG>8-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jolley-1990" NAME="Jolley 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L</AU>
<TI>Trial of brief intermittant neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years</TI>
<SO>British Medical Journal</SO>
<YR>1990</YR>
<VL>301</VL>
<PG>837-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meco-1985" NAME="Meco 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meco G, Falaschi P, Casacchia M, Rocco A, Petrini P, Rosa M, Agnoli A</AU>
<TI>Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia</TI>
<SO>Advanced Biochemical Psychopharmacology</SO>
<YR>1985</YR>
<VL>40</VL>
<PG>89-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meco-1987" NAME="Meco 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Meco G, Aniello R, Lestingi L, Petrini P, Castellano A, Casacchia M</AU>
<TI>Haloperidol decanoate (a new depot neuroleptic drug): double-blind study versus fluphenazine decanoate in schizophreniform disorders and chronic schizophrenia</TI>
<SO>Schizophrenia: an integrative view</SO>
<YR>1987</YR>
<PG>155-70</PG>
<ED>Cazulla CL, Invernizzi G, Bressi C</ED>
<CY>Milan, Italy</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-1986" NAME="Nair 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, Thavundayil JX, Achim A, Lizondo E, Nayak R</AU>
<TI>A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>1</NO>
<PG>30-7S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapp-1986" NAME="Rapp 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapp W, Hellbom E, Norrman O, Palm U, Rodhe K, Forsman A, Larsson M</AU>
<TI>A double-blind crossover study comparing haloperidol decanoate and perphanazine enanthate</TI>
<SO>Current Therapeutic Research</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>5</NO>
<PG>665-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roose-1982" NAME="Roose 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roose K</AU>
<TI>Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanaote in schizophrenia and other chronic psychoses</TI>
<SO>Acta Psychiatrica Belgique</SO>
<YR>1982</YR>
<VL>82</VL>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ushakov-1990" NAME="Ushakov 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ushakov IV, Kravchenko NE, Kopeiko GI, Kalugina LI, Mirzoian MG</AU>
<TI>Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia</TI>
<TO>Klinicheskii ekonomicheskii podkhod k otsenke sravnitel'noi effektivnosti moditena-depo i galoperidola dekanoata v podderzhi-vaiushchei terapii u bol'nykh pristupoobraznoi shizofreniei</TO>
<SO>Zh Nevropatol-Psikhiatria Im-S-S-Korsakova</SO>
<YR>1990</YR>
<VL>90</VL>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Putten-1986" NAME="Van Putten 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Putten T, Marder SR</AU>
<TI>Low-dose treatment strategies</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>Suppl 5</NO>
<PG>12-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varma-1989" NAME="Varma 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varma VK, Kulhara P</AU>
<TI>Open drug trial with haloperidol decanoate injections in schizophrenia</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>2</NO>
<PG>144-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-1996" NAME="Wei 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei F, Jann MW, Lin H, Piao-Chien C, Chang W</AU>
<TI>A practical loading dose method converting schizophrenic patients from oral to depot haloperidol therapy</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>7</NO>
<PG>298-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden-1995" NAME="Weiden 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A</AU>
<TI>Post-discharge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen</TI>
<SO>Psychiatric Services</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1049-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiles-1990" NAME="Wiles 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiles DM, McCreadie RG, Whitehead A</AU>
<TI>Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1990</YR>
<VL>101</VL>
<PG>274-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Youssef-1991" NAME="Youssef 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Youssef HA</AU>
<TI>Duration of neuroleptic treatment and relapse rate: a five-year follow-up study with haloperidol decanoate</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>Suppl 2</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zonda-1992" NAME="Zonda 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zonda T, Kovari E</AU>
<TI>Use of haloperidol decanoate in psychiatric diseases</TI>
<SO>Therapia Hungarica</SO>
<YR>1992</YR>
<VL>40</VL>
<NO>2</NO>
<PG>64-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-10-30 13:19:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bernardi-1992" MODIFIED="2008-10-30 13:19:42 +0000" MODIFIED_BY="[Empty name]" NAME="Bernardi 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-30 13:19:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Awaiting translation.&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 13:19:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernardi F, Bocchetta A, del Zompo M, Volonte MV, et al</AU>
<TI>Efficacy and tolerability to bromperidol decanoate in psychotic patients formerly treated with haloperidol or chlorpromazine</TI>
<TO>Efficacia terapeutica e tollerabilita del bromperidolo decanoato in pazienti psicotici gia in trattamento con aloperidolo o clorpromazina</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1992</YR>
<VL>27</VL>
<PG>271-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castellani-1988" MODIFIED="2008-10-30 13:15:09 +0000" MODIFIED_BY="[Empty name]" NAME="Castellani 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-10-30 13:15:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;Awaiting translation.&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 13:15:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castellini A, Lorini M</AU>
<TO>Flufenazina decanoato e aloperidolo decanoato: due neurolettici a confronto nella patologia psichiatrica non acuta studio crossover a lunga termine</TO>
<SO>Incomplete reference</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morasiewicz-1995" NAME="Morasiewicz 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Awaiting translation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morasiewicz J, Baranowski P, Borys J, JanskaSkomorowska M, Kiejna A</AU>
<TI>Evaluation of clinical usefulness of Decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia</TI>
<TO>Ocena przydatnosci klinicznej preparatu decaldol (dekanonian haloperidolu) produkcji wzf polfaw warszawie w dlugotrwalym leczeniu schizofrenii</TO>
<SO>Psychiatria Polska</SO>
<YR>1995</YR>
<VL>29</VL>
<PG>405-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-1992" NAME="Rossi 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Awaiting translation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi P, Chini C, Casale A, Fusi A, Madonna M, Monaci C, Carta I</AU>
<TI>Action of bromperidol decanoate in the treatment of negative symptoms of schizophrenia - comparison with haloperidol decanoate</TI>
<TO>Azione del bromperidolo decanoato nel trattamento dei sintomi negativi della schizofrenia - confronto con l'aloperidolo decanoato</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1992</YR>
<VL>27</VL>
<PG>265-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-30 13:19:12 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-30 13:19:12 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaes_x002d_Jorgenson-1985" MODIFIED="2008-10-30 13:18:33 +0000" MODIFIED_BY="[Empty name]" NAME="Aaes-Jorgenson 1985" TYPE="CONFERENCE_PROC">
<AU>Aaes-Jorgensen A</AU>
<TI>Pharmacokinetics of oral and depot neuoleptics - clinical relevance</TI>
<SO>Symposium Espo</SO>
<YR>1985</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agius-1994" NAME="Agius 1994" TYPE="JOURNAL_ARTICLE">
<AU>Agius AM, Reid AP, Hamilton CAD</AU>
<TI>Patient compliance with short-term topical aural antibiotic therapy</TI>
<SO>Clinical Otolaryngology</SO>
<YR>1994</YR>
<VL>19</VL>
<PG>138-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altamura-1987" NAME="Altamura 1987" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, Mauri MC, Guecetti G, Cazzullo CL</AU>
<TI>Fluphenazine decanoate in acute and maintenance therapy of schizophrenia</TI>
<SO>Progress Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1987</YR>
<VL>11</VL>
<PG>613-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="HLDC020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Asberg-1978" NAME="Asberg 1978" TYPE="JOURNAL_ARTICLE">
<AU>Asberg M, Montgomery SA, Perris C, Schalling D, Sedavll GA</AU>
<TI>A comprehensive psychopathological rating scale</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1978</YR>
<VL>271</VL>
<PG>5-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1994" NAME="Barnes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TRE, Curson DA</AU>
<TI>Long term depot antipsychotics. A risk benefit assessment</TI>
<SO>Drug Safety</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>6</NO>
<PG>464-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L</AU>
<TI>Extrapyramidal symptom rating scale</TI>
<SO>Canadian Journal of Neurological Science</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-David-1994" NAME="David 1994" TYPE="BOOK">
<AU>David AS, Cutting JC, editors</AU>
<SO>The neuropsychology of schizophrenia</SO>
<YR>1994</YR>
<PB>Lawrence Erlbaum Associates</PB>
<CY>Hove, E. Sussex</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1986" NAME="Davis 1986" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Andriukatis S</AU>
<TI>The natural course of schizophrenia and effective maintenance drug therapy</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>Suppl 1</NO>
<PG>2-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dencker-1980" NAME="Dencker 1980" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Lepp M, Malm U</AU>
<TI>Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1980</YR>
<VL>61</VL>
<NO>279</NO>
<PG>64-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DoH-1996" NAME="DoH 1996" TYPE="BOOK">
<AU>Department of Health</AU>
<SO>NHS Executive. Burdens of disease: a discussion document</SO>
<YR>1996</YR>
<PB>HMSO</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feighner-1972" NAME="Feighner 1972" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Robins E, Guze S, Woodruff RA, Winokur G, Munoz R</AU>
<TI>Diagnostic criteria for use in psychiatric research</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>US Government Printing Office</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="National Institute of Mental Health Publication No. 76-338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1979" NAME="Haynes 1979" TYPE="BOOK">
<AU>Haynes RB, Taylor WD, Sackett DL</AU>
<SO>Compliance in health care</SO>
<YR>1979</YR>
<PB>John Hopkins University Press</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heresco_x002d_Levy-1989" NAME="Heresco-Levy 1989" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Greenberg D, Wittman L, Dasberg H, Lerer B</AU>
<TI>Prescribing patterns of neuroactive drugs in 98 schizophrenic patients</TI>
<SO>Israel Journal of Psychiatry and Related Sciences</SO>
<YR>1989</YR>
<VL>26</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honigfeld-1962" NAME="Honigfeld 1962" TYPE="JOURNAL_ARTICLE">
<AU>Honigfeld G, Gillis RD, Klett CJ</AU>
<TI>NOSIE-30: A treatment sensitive ward behavior scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen ASO</AU>
<TI>Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine Monograph Supplement</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>1-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1990" NAME="Johnson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DA, Wright NF</AU>
<TI>Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>156</VL>
<PG>827-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1986" NAME="Kane 1986" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Woerner M, Sarantakos S</AU>
<TI>Depot neuroleptics: a comparison review of standard, intermediate and low-dose regimens</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>Suppl 5</NO>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1998" NAME="Kane 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR</AU>
<TI>Guidelines for depot antipsychotic treatment in schizophrenia</TI>
<SO>European Neuropschopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>55-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krawiecka-1977" NAME="Krawiecka 1977" TYPE="JOURNAL_ARTICLE">
<AU>Krawiecka M, Goldberg D, Vaughan M</AU>
<TI>A standardised psychiatric assessment scale for rating psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>55</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leff-1971" NAME="Leff 1971" TYPE="JOURNAL_ARTICLE">
<AU>Leff JP, Wing JK</AU>
<TI>Trial of maintenance therapy in schizophrenia</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>3</VL>
<PG>559-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leff-1973" NAME="Leff 1973" TYPE="JOURNAL_ARTICLE">
<AU>Leff JP, Hirsch SR, Gaind R, Rhhode PD</AU>
<TI>Outpatient maintenace of chronic schizophrenic patients with long acting fluphenazine: double-blind placebo trial</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>1</VL>
<PG>633-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lingjerde-1987" NAME="Lingjerde 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lingjerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K</AU>
<TI>The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>Suppl</NO>
<PG>334</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1999" MODIFIED="2008-10-30 13:19:12 +0000" MODIFIED_BY="[Empty name]" NAME="Mulrow 1999" TYPE="COCHRANE_REVIEW">
<AU>Mulrow CD, Oxman A</AU>
<TI>The Cochrane Handbook [updated 1 March 1999]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<PB>Update Software; 1996-. Updated quarterly</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-1997" NAME="Pereira 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pereira S, Pinto R</AU>
<TI>A survey of the attitudes of chronic psychiatric patients living in the community toward their medication</TI>
<SO>Acta Psychiatrica Scandanavica</SO>
<YR>1997</YR>
<VL>95</VL>
<PG>464-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reyntijens-1982" NAME="Reyntijens 1982" TYPE="JOURNAL_ARTICLE">
<AU>Reyntijens AJM, Heykants JJP, Woestenborghs RJH</AU>
<TI>Pharmacokinetics of haloperidol decanoate</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1982</YR>
<VL>17</VL>
<PG>238-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1994" NAME="Schulz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Grimes DA, Altman DG</AU>
<TI>Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>125-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatria Scandinavia Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1977" NAME="Spitzer 1977" TYPE="BOOK">
<AU>Spitzer RL, Endicott J, Robins E</AU>
<SO>Research diagnostic criteria for a selected group of functional disorders</SO>
<YR>1977</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bechelli-1985">
<CHAR_METHODS>
<P>Allocation: randomised, stratified by Schizophrenia subgroups.<BR/>Blindness: double.<BR/>Duration: 6 months (preceded by 7 day washout).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>History: &gt;2 episodes, stabilized for 3 months, duration ill - mean 12 yrs (HD) 9 yrs (PP), informed consent given.<BR/>N = 41.<BR/>Age: 19-50 yrs (mean range 30-33 yrs).<BR/>Sex: all male.<BR/>Race: caucasian.<BR/>Setting: out-patient clinic.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 100mg/injection, monthly, range 50-100mg/injection. N=21.<BR/>2. Pipothiazine palmitate: dose mean 75 (**65)mg/ injection, monthly, range 50- 125mg/injection. N=20.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (BPRS).<BR/>Leaving the study early. <BR/>Additional medication.<BR/>Side effects (Bordeleau Scale/AIMS).</P>
<P>Unable to use - <BR/>Global Impression (CGI - no data).<BR/>Weight measures (non-clinical outcomes, data not usuable).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Spitzer 1997<BR/>** The mean dose of PP is given as 75mg in the abstract and 65mg in the paper.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chouinard-1984">
<CHAR_METHODS>
<P>Allocation: randomised, stratified by sex &amp; past frequency of depot administration.<BR/>Blindness: double.<BR/>Duration: 8 months.<BR/>Statistics: last observation carried forward.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM III).<BR/>History: on depot &gt;3 months, duration ill - mean 16 yrs, range 3-38, informed consent given.<BR/>N=72.<BR/>Age: mean 44 yrs, range 18-66.<BR/>Sex: 36 M, 36 F.<BR/>Setting: community.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 225mg/injection, 2-4 weekly, range 15-900mg/injection. N=36.<BR/>2. Fluphenazine decanoate: dose mean 75mg/injection, 2-4 weekly, range 2.5-300mg/injection. N=36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global Impression (CGI).<BR/>Mental state (BPRS).<BR/>Leaving the study early.<BR/>Additional medication.</P>
<P>Unable to use - <BR/>Side effects (ESRS - authors own scale*, TESF - no data reported).<BR/>Physiological measures (prolactin, drug plasma levels - non clinical outcomes, data not usable).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Marshall et al, 1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cookson-1986">
<CHAR_METHODS>
<P>Allocation: randomised - seperate sequences for males and females. <BR/>Blindness: double.<BR/>Duration: 1 year.<BR/>Statistics: last observation carried forward.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>History: 1 year of treatment with fluphenazine decanoate, overweight BMI 25+, physically fit, stable during prev yr.<BR/>N= 19.<BR/>Age: range HD 26-57 yrs/ FD 35-60 yrs.<BR/>Sex: 9 M, 10 F.<BR/>Setting: community (depot injection clinic).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean not specified, frequency same as previous depot. N=10.<BR/>2. Fluphenazine decanoate: dose mean not specified. N=9.<BR/>Dose ratio: 4:1 (HD/FD).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state (CPRS, Kraweicka -Goldberg Scale - no data).<BR/>Side effects (Simpson &amp; Angus Scale/ AIMS - no data).<BR/>Physiological measures (prolactin), weight measures - non clinical outcomes, data not usuable).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No usuable continuous data.<BR/>Authors contacted - no reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Eberhard-1986">
<CHAR_METHODS>
<P>Allocation: randomised, blocks of 6.<BR/>Blindness: double.<BR/>Duration: 24 weeks - no washout period.<BR/>Crossover X 2.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM III).<BR/>History: previously on antipsychotics (both depot/oral), duration ill - range 1-6 yrs, consent given.<BR/>N=32.<BR/>Age: median 38 yrs, range 25-60.<BR/>Sex: 17 M, 15 F.<BR/>Setting: 10 inpatients, 28 community, multicentre.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 131mg/injection (start)- 151mg/injection (24 wks), last 3 injections fixed dose. N=16.<BR/>2. Flupenthixol decanoate: dose mean 56mg/injection (start)- 66mg/injection (24 wks), last 3 injections fixed dose. N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (CPRS).<BR/>Leaving the study early.<BR/>Additional medication.<BR/>Side effects - depression.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Eklund-1991">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 48 weeks (preceded by 15 week single blind 60mg HD/ month). <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>N=56<BR/>Age: mean ~ 52 yrs (SD ~ 12), range 25-65.<BR/>Sex: 37 F, 19 M.<BR/>Setting: 37 community, 19 hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 60mg/ injection (fixed dose regimen), every 4 weeks. N=18/N=20*<BR/>2. Placebo: N=23</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use - <BR/>Additional medication (&gt;30% attrition)<BR/>Relapse (&gt;30% attrition).<BR/>Side effects (EPSS - &gt;30% attrition).<BR/>Mental state (CPRS - no SD).<BR/>Physiological measures (plasma levels).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* N in HD group in abstract differs from N in paper.<BR/>Authors contacted - no reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kissling-1985">
<CHAR_METHODS>
<P>Allocation: randomised, flip of a coin.<BR/>Blindness: double.<BR/>Duration: 6 months.<BR/>Statistics: last observation carried forward.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia/ schizoaffective psychosis (DSM III).<BR/>History: on oral medication, need depot treatment for &gt;6 months, informed consent given.<BR/>N=54.<BR/>Age: ~ 30 years (SD ~11).<BR/>Sex: 24 M, 7 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 80mg/ injection (actual dose given 50mg), monthly. N=32.<BR/>2. Fluphenazine decanoate: dose mean 21mg/ injection (actual dose given 25mg), every 2 weeks. N=22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early. </P>
<P>Unable to use - <BR/>Mental state (BPRS).*<BR/>Additional medication (anticholinergics).*<BR/>Side effects (EPMS, DOTES, STESS).*<BR/>Physiological Measures (serum levels - non clinical outcomes, data not usable).*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*The drop out rate after 6 months for FD=60%, HD=30%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McKane-1987">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 60 weeks (preceded by 12 week 'run in' period where additional medication allowed).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (Fiegner criteria*).<BR/>History: on antipsychotics, duration ill - mean 31 yrs, range 10-50, next of kin gave consent.<BR/>N=38.<BR/>Age: mean 56 yrs, range 31- 71.<BR/>Sex : 22 M, 16 F.<BR/>Setting: in hospital.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanaote: initial dose mean 127 mg/injection, week 12 dose mean 120mg/ injection, monthly. N=17.<BR/>2. Fluphenazine decanoate: initial mean dose 106mg/ injection, week 12 dose mean 105/ injection, monthly. N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (Krawiecka scale).<BR/>Leaving the study early.<BR/>Additional medication.<BR/>Side effects (AIMS).<BR/>Parkinsonism (Simpson &amp; Angus).<BR/>Behaviour (Wing Ward Behaviour Scale).</P>
<P>Unable to use - <BR/>Global impresson (Global 5-point scale - no data).<BR/>Physiological measures (prolactin, drug plasma levels - non clinical outcomes, data not usable).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Fiegner 1972</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wistedt-1984">
<CHAR_METHODS>
<P>Allocation: randomisation list, blocks of six.<BR/>Blindness: double.<BR/>Duration: 20 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>History: duration ill - range 0-12 yrs, informed consent given.<BR/>N=51.<BR/>Age range: 21-63 yrs.<BR/>Sex: 33 M, 18 F.<BR/>Setting: 4 weeks in hospital, community thereafter, multicentre.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 122mg/injection, monthly. N=25.<BR/>2. Fluphenazine decanoate: dose mean 84mg/injection, monthly. N=26.*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global impression (CGI).<BR/>Mental state (CPRS).<BR/>Leaving the study early.<BR/>Additional medication.<BR/>Side effects (AIMS, EPS).</P>
<P>Unable to use - <BR/>Physiological measures (drug plasma levels - non-clinical outcomes, data not usable).<BR/>Weight changes (non-clincal outcomes, data not usable).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose ratio :1:1.4 (FD/HD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wistedt-1991">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 9 months (preceded by 3 months on either depot).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM III).<BR/>History: BPRS total score 5-26, duration ill - mean &gt;2yrs.<BR/>N=64.<BR/>Age: range 25-60 yrs.<BR/>Sex: 28 M, 33 F.<BR/>Setting: community, multicentre.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 92mg/IM, range 38-200mg/injection, monthly. N=33.<BR/>2. Zuclopenthixol decanoate: dose mean 284mg/IM, range 100-600mg/injection, monthly. N=23.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Global Impression (CGI).<BR/>Mental state (BPRS, MADRS).<BR/>Side effects (Simpson &amp; Angus, UKU).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Initial 3 month dose adjustment period + supplementary medication, then 6 months where dose constant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zissis-1982">
<CHAR_METHODS>
<P>Allocation: randomised - predetermined code.<BR/>Blindness: double.<BR/>Duration: 16 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (Feighner criteria).<BR/>History: on antipsychotics &gt;2yrs, informed consent given, duration hospitalized ~ 14 yrs.<BR/>N=32.<BR/>Age: mean ~ 46 yrs (range 28- 60).<BR/>Sex: 12 F, 4 M.<BR/>Setting: in hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose mean 150mg/IM/month, initially, range 0.5-1.5ml/IM, dose adapted to side effects. N=16.<BR/>2. Placebo IM. N=16.<BR/>Haloperidol given orally if individual deteriorated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: withdrawn due to lack of effect.<BR/>Additional medication.</P>
<P>Unable to use - <BR/>Global Impression (CGI - no data reported)*. <BR/>Mental state (BPRS - no SD)**.<BR/>Behaviour (NOSIE - no SD)**.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract &amp; paper differed on numbers withdrawn - used data in body of paper.<BR/>&gt;30% withdrawn due to lack of effect but all followed up.<BR/>* reported to be not different between groups.<BR/>** reported as statistically different.<BR/>Authors contacted - no reply.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zuardi-1983">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindiness: double.<BR/>Duration: 4 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (ICD-9).<BR/>History: same drugs for 2 months, stable symptoms 1 month, duration hospitalized 0.3 - 26 yrs.<BR/>N=22.<BR/>Age: range 26- 63 yrs.<BR/>Sex: 13 M, 9 F.<BR/>Setting: in hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol decanoate: dose schedule individualized. N=11.<BR/>2. Haloperidol oral: dose schedule individualized. N=11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (BPRS).*<BR/>Leaving the study early.<BR/>Additional medication. <BR/>Side effects (Bordeleau Scale).*</P>
<P>Unable to use - <BR/>Global Impression (CGI - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Authors supplied additional BPRS &amp; Bordeleau scale data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tools<BR/>DSM III - Diagnostic Statistical Manual, version 3.<BR/>ICD-9 - International Calssification of Diseases, version 9.<BR/>RDC - Research Diagnostic Criteria.</P>
<P>Rating scales<BR/>Global impression<BR/>CGI - Clinical Global Impression.</P>
<P>Mental state<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>CPRS - Comprehensive Psychopathological Rating Scale.</P>
<P>Side effects<BR/>AIMS - Abnormal Involuntary Movement Side effects.<BR/>DOTES - Dosage Record &amp; Treatment Emergent Symptom Scale.<BR/>EPMS - Extrapyramidal Motor Side-effects.<BR/>EPSS - Extrapyramidal Side-effects Symptoms.<BR/>MARDRS- Montgomery-Asberg Depression Rating Scale.<BR/>STESS - Total Score of Side Effects Self Rating.<BR/>TESF - Treatment Emergent Symptom Form.<BR/>UKU - Side Effects Rating Scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Angus-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: 'double blind'.<BR/>Participants: those with a psychotic illness.<BR/>Interventions: amantadine hydrochloride versus neuroleptic, not haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baastrup-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with exacerbation of chronic psychosis.<BR/>Interventions: haloperidol decanoate and oral versus zuclopenthixol acetate versus zuclopenthixol decanoate.<BR/>Outcomes: no usable data, haloperidol decanoate and oral data pooled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bucci-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cookson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: 'double blind'.<BR/>Participants: those with schizophrenia.<BR/>Interventions: haloperidol decanoate versus fluphenazine decanoate.<BR/>Outcomes: no usable data, authors contacted and have replied redirecting the request to a third party who has been contacted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Curson-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: fluphenazine decanoate versus placebo, not haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deberdt-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dencker-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: clopenthixol depot versus flupehthixol depot, not haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dencker-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: haloperidol decanoate versus perphanazine decanoate.<BR/>Outcomes: no usable data, authors contacted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fernando-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gianelli-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jolley-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: fluphenazine decanoate, not haloperidol decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meco-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meco-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nair-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapp-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: haloperidol decanoate versus perphenazine decanoate.<BR/>Outcomes: no usable data, authors contacted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roose-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ushakov-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: haloperidol decanoate versus fluphenazine.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Putten-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Varma-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wei-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiden-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wiles-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: 'double blind'.<BR/>Participants: those with schizophrenia.<BR/>Interventions: haloperidol decanoate versus fluphenazine decanoate.<BR/>Outcomes: no usable data, authors contacted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Youssef-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zonda-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Behaviour scale<BR/>NOSIE - Nurses Observation Scale for Inpatient Evaluation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Bernardi-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Castellani-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Morasiewicz-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rossi-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bechelli-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eberhard-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eklund-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kissling-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McKane-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wistedt-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wistedt-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zissis-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zuardi-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>HALOPERIDOL DECANOATE vs PLACEBO</NAME>
<DICH_OUTCOME CHI2="2.2391049026000616" CI_END="0.21151187871427174" CI_START="0.034511700109775924" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.08543789866237492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="29" I2="55.339296571643686" I2_Q="55.339296571643686" ID="CMP-001.01" LOG_CI_END="-0.6746652372005497" LOG_CI_START="-1.4620336460371768" LOG_EFFECT_SIZE="-1.0683494416188632" METHOD="PETO" NO="1" P_CHI2="0.1345589525653038" P_Q="0.1345589525653038" P_Z="1.0445550796459815E-7" Q="2.2391049026000616" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="38" WEIGHT="100.0" Z="5.318797160201847">
<NAME>Behaviour: Not completing the study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.1534391157238621" CI_START="0.009543792282690287" DF="0.0" EFFECT_SIZE="0.03826736270646589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.814063913023736" LOG_CI_START="-2.0202790215027497" LOG_EFFECT_SIZE="-1.417171467263243" NO="1" P_CHI2="1.0" P_Z="4.114982996293171E-6" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="42.60950056801447" Z="4.605488716280768">
<NAME>short term - withdrawn by trialists due to lack of effect</NAME>
<DICH_DATA CI_END="0.1534391157238621" CI_START="0.009543792282690287" EFFECT_SIZE="0.03826736270646589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.814063913023736" LOG_CI_START="-2.0202790215027497" LOG_EFFECT_SIZE="-1.417171467263243" ORDER="234" O_E="-6.5" SE="0.7085367255816566" STUDY_ID="STD-Zissis-1982" TOTAL_1="16" TOTAL_2="16" VAR="1.9919354838709675" WEIGHT="42.60950056801447"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5132198201369261" CI_START="0.04687730132450013" DF="0.0" EFFECT_SIZE="0.15510757606985046" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.2896965798694342" LOG_CI_START="-1.3290373981335952" LOG_EFFECT_SIZE="-0.8093669890015147" NO="2" P_CHI2="1.0" P_Z="0.002268910266108064" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="57.39049943198553" Z="3.0525697073419664">
<NAME>medium term - leaving the study early</NAME>
<DICH_DATA CI_END="0.5132198201369261" CI_START="0.04687730132450013" EFFECT_SIZE="0.15510757606985046" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.2896965798694342" LOG_CI_START="-1.3290373981335952" LOG_EFFECT_SIZE="-0.8093669890015147" ORDER="235" O_E="-5.0" SE="0.6105139414683932" STUDY_ID="STD-Eklund-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.682926829268293" WEIGHT="57.39049943198553"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5524494305164349" CI_START="0.03532675895183791" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13970056501293837" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.25770746977462133" LOG_CI_START="-1.451896205019132" LOG_EFFECT_SIZE="-0.8548018373968767" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.005017789676754614" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.805889497648807">
<NAME>Global impression: Needing additional antipsychotic treatment - by 4 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5524494305164349" CI_START="0.03532675895183791" EFFECT_SIZE="0.13970056501293837" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.25770746977462133" LOG_CI_START="-1.451896205019132" LOG_EFFECT_SIZE="-0.8548018373968767" ORDER="236" O_E="-4.0" SE="0.7014723744122017" STUDY_ID="STD-Zissis-1982" TOTAL_1="16" TOTAL_2="16" VAR="2.032258064516129" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.1534391157238621" CI_START="0.009543792282690287" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.03826736270646589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.814063913023736" LOG_CI_START="-2.0202790215027497" LOG_EFFECT_SIZE="-1.417171467263243" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="4.114982996293171E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="4.605488716280768">
<NAME>Mental state: No discernable effect - by 4 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1534391157238621" CI_START="0.009543792282690287" EFFECT_SIZE="0.03826736270646589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.814063913023736" LOG_CI_START="-2.0202790215027497" LOG_EFFECT_SIZE="-1.417171467263243" ORDER="237" O_E="-6.5" SE="0.7085367255816566" STUDY_ID="STD-Zissis-1982" TOTAL_1="16" TOTAL_2="16" VAR="1.9919354838709675" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8855061616208203" CI_START="0.032671201426819146" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1700898297106658" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.052808412510482676" LOG_CI_START="-1.4858348948038955" LOG_EFFECT_SIZE="-0.769321653657189" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.03534207703654317" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.1044171232366056">
<NAME>Side effects: 1. Anticholinergic problems - blurred vision - by 4 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8855061616208205" CI_START="0.03267120142681913" EFFECT_SIZE="0.1700898297106658" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.052808412510482565" LOG_CI_START="-1.4858348948038955" LOG_EFFECT_SIZE="-0.769321653657189" ORDER="238" O_E="-2.5" SE="0.8417668492946421" STUDY_ID="STD-Zissis-1982" TOTAL_1="16" TOTAL_2="16" VAR="1.411290322580645" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.091095888555843" CI_START="0.24443328321815502" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6118396587657032" LOG_CI_START="-0.6118396587657032" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Side effects: 2. Movement disorders - tremor - by 4 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.091095888555842" CI_START="0.24443328321815505" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.6118396587657031" LOG_CI_START="-0.6118396587657031" LOG_EFFECT_SIZE="0.0" ORDER="239" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Zissis-1982" TOTAL_1="16" TOTAL_2="16" VAR="1.935483870967742" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>HALOPERIDOL DECANOATE vs ORAL HALOPERIDOL</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.281412708514352" CI_START="0.0869416285830842" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6101090013387374" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.6315870938448973" LOG_CI_START="-1.0607722289022286" LOG_EFFECT_SIZE="-0.2145925675286656" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6191537085219236" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="0.49705012174770846">
<NAME>Global impression: Not improved - at 4 months (CGI)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.281412708514352" CI_START="0.0869416285830842" EFFECT_SIZE="0.6101090013387374" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.6315870938448973" LOG_CI_START="-1.0607722289022286" LOG_EFFECT_SIZE="-0.2145925675286656" ORDER="240" O_E="-0.5" SE="0.9941002434954168" STUDY_ID="STD-Zuardi-1983" TOTAL_1="11" TOTAL_2="11" VAR="1.0119047619047619" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.594515426282861" CI_START="-2.1945154262828632" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.24497521320241455" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="1.1626409890257499">
<NAME>Mental state: BPRS - at 4 months (endpoint score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.594515426282861" CI_START="-2.1945154262828632" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="31.8" MEAN_2="28.6" ORDER="241" SD_1="6.2" SD_2="6.7" SE="2.7523543640771524" STUDY_ID="STD-Zuardi-1983" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="26.673477696278894" CI_START="0.3866109481016188" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.211270543153561" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.426079642830476" LOG_CI_START="-0.41272585172288845" LOG_EFFECT_SIZE="0.5066768955537938" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2800872273165712" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="1.0801234497346432">
<NAME>Side effects: 1. Movement disorders - needing anticholinergic drugs.</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.673477696278894" CI_START="0.3866109481016188" EFFECT_SIZE="3.211270543153561" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.426079642830476" LOG_CI_START="-0.41272585172288845" LOG_EFFECT_SIZE="0.5066768955537938" ORDER="242" O_E="1.0" SE="1.0801234497346435" STUDY_ID="STD-Zuardi-1983" TOTAL_1="11" TOTAL_2="11" VAR="0.8571428571428571" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Side effects: 2. Extrapyramidal symptoms - skewed data (Bordeleau Scale).</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="10" STUDY_ID="STD-Zuardi-1983">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 1.5 SD 1.7. N=11.<BR/>2. Haloperidol tablets - mean 1.2 SD 1.6. N=11.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>HALOPERIDOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.010048971145785235" CI_END="2.3682434029349015" CI_START="0.009054101619566761" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.14643195153395036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3744263361923824" LOG_CI_START="-2.043154635468176" LOG_EFFECT_SIZE="-0.834364149637897" METHOD="PETO" NO="1" P_CHI2="0.9201501737904844" P_Q="1.0" P_Z="0.1761005223850133" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="52" WEIGHT="100.0" Z="1.352859492568239">
<NAME>Death</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.4187859330849335" CI_START="0.0025181544853915276" EFFECT_SIZE="0.1271357329320356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8074528921774701" LOG_CI_START="-2.598917630028384" LOG_EFFECT_SIZE="-0.8957323689254568" ORDER="244" O_E="-0.5151515151515151" SE="2.0009189065497472" STUDY_ID="STD-McKane-1987" TOTAL_1="17" TOTAL_2="16" VAR="0.2497704315886134" WEIGHT="50.37073474200479"/>
<DICH_DATA CI_END="8.785812867648843" CI_START="0.0032513213307483932" EFFECT_SIZE="0.1690133154060661" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9437819488253871" LOG_CI_START="-2.4879401067036153" LOG_EFFECT_SIZE="-0.7720790789391143" ORDER="245" O_E="-0.4375" SE="2.0158105227158787" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="0.24609375" WEIGHT="49.629265257995215"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003243294697743579" CI_END="2.2950488736971018" CI_START="0.17346549069894157" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6309609964600988" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.36079193839221585" LOG_CI_START="-0.7607869110155003" LOG_EFFECT_SIZE="-0.19999748631164224" METHOD="PETO" NO="2" P_CHI2="0.9545851110674779" P_Q="1.0" P_Z="0.4845564239398047" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="56" WEIGHT="100.0" Z="0.6989929782937016">
<NAME>Global impression: 1. Needing additional antipsychotic treatment</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.855419600503489" CI_START="0.09562094004703635" EFFECT_SIZE="0.6071728308117162" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5860716509385957" LOG_CI_START="-1.0194469910812058" LOG_EFFECT_SIZE="-0.21668767007130504" ORDER="246" O_E="-0.5609756097560976" SE="0.9430895977678841" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" VAR="1.124330755502677" WEIGHT="48.80102191572832"/>
<DICH_DATA CI_END="3.9778267489599783" CI_START="0.10769018613433394" EFFECT_SIZE="0.6545020267391328" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.599645863853979" LOG_CI_START="-0.9678238723928552" LOG_EFFECT_SIZE="-0.18408900426943803" ORDER="247" O_E="-0.5" SE="0.920739482171722" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" VAR="1.1795774647887325" WEIGHT="51.19897808427169"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.09508398667905518" CI_END="0.3610000483255947" CI_START="-0.22069166218522357" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07015419307018557" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.7578107834056914" P_Q="1.0" P_Z="0.6363858753418976" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="0.4727579551074794">
<NAME>Global impression: 2. Clinical Global Impression (endpoint score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.44724504905615303" CI_START="-0.24724504905615285" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.8" ORDER="248" SD_1="0.7" SD_2="0.8" SE="0.17716909687891083" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" WEIGHT="70.15419307018551"/>
<CONT_DATA CI_END="0.5323793682865336" CI_START="-0.5323793682865336" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.9" ORDER="249" SD_1="1.0" SD_2="1.0" SE="0.2716271178888358" STUDY_ID="STD-Wistedt-1991" TOTAL_1="23" TOTAL_2="33" WEIGHT="29.84580692981449"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Global impression: 3. Clinical Global Impression (skewed data, high=poor).</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="17" STUDY_ID="STD-Wistedt-1984">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 2.9 SD 1.5. N=25. <BR/>2. Fluphenazine decanoate - mean 2.9 SD 2.0. N=26.<BR/>
<BR/>t</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.7538510405630423" CI_END="2.423074629200485" CI_START="0.6466306584734509" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2517325365309566" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.38436679034503174" LOG_CI_START="-0.18934370818379895" LOG_EFFECT_SIZE="0.09751154108061638" METHOD="PETO" NO="5" P_CHI2="0.7099458147718408" P_Q="1.0" P_Z="0.5052473156082218" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="162" WEIGHT="99.99999999999999" Z="0.66625627066297">
<NAME>Mental state: 1. Relapse</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.284238322315434" CI_START="0.12353299588152161" EFFECT_SIZE="0.948600960715629" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.862384146399835" LOG_CI_START="-0.9082170260858925" LOG_EFFECT_SIZE="-0.022916439843028734" ORDER="251" O_E="-0.04878048780487809" SE="1.040059893335274" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" VAR="0.9244497323022011" WEIGHT="10.498907262294686"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="252" O_E="-0.5" SE="2.0" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" VAR="0.25" WEIGHT="2.839231516717723"/>
<DICH_DATA CI_END="130.0462090355012" CI_START="0.429832178234132" EFFECT_SIZE="7.476499535265201" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1140976966398526" LOG_CI_START="-0.3667010753350041" LOG_EFFECT_SIZE="0.8736983106524245" ORDER="253" O_E="0.9473684210526316" SE="1.457233478810004" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="5.348136928997373"/>
<DICH_DATA CI_END="5.73975951757274" CI_START="0.17422332711647917" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7588936968615585" LOG_CI_START="-0.7588936968615584" LOG_EFFECT_SIZE="0.0" ORDER="254" O_E="0.0" SE="0.8915558282417286" STUDY_ID="STD-Eberhard-1986" TOTAL_1="16" TOTAL_2="16" VAR="1.2580645161290323" WEIGHT="14.287745697031122"/>
<DICH_DATA CI_END="3.513766947151511" CI_START="0.2845948564718173" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.5457729532541697" LOG_CI_START="-0.5457729532541697" LOG_EFFECT_SIZE="0.0" ORDER="255" O_E="0.0" SE="0.6411794687223782" STUDY_ID="STD-McKane-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.4324324324324325" WEIGHT="27.624955297794063"/>
<DICH_DATA CI_END="4.666284148900026" CI_START="0.2347747529804471" EFFECT_SIZE="1.0466736398680245" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6689711812091163" LOG_CI_START="-0.629348607725993" LOG_EFFECT_SIZE="0.01981128674156158" ORDER="256" O_E="0.07843137254901977" SE="0.7626394708070884" STUDY_ID="STD-Wistedt-1984" TOTAL_1="25" TOTAL_2="26" VAR="1.7193387158785083" WEIGHT="19.526402680140958"/>
<DICH_DATA CI_END="10.368126766168231" CI_START="0.5355555541358374" EFFECT_SIZE="2.3564184423836605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.015700298471618" LOG_CI_START="-0.27119547235175784" LOG_EFFECT_SIZE="0.3722524130599301" ORDER="257" O_E="1.5" SE="0.7559289460184544" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="1.75" WEIGHT="19.87462061702406"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.09579260141534768" CI_END="2.7150836889567236" CI_START="-0.9671031262385481" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8739902813590879" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.7569383441385615" P_Q="1.0" P_Z="0.35215386214623334" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.9304196447789402">
<NAME>Mental state: 2. BPRS (endpoint score, high=poor)</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.431961036814037" CI_START="-1.2319610368140412" EFFECT_SIZE="1.0999999999999979" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="19.3" ORDER="258" SD_1="5.2" SD_2="1.6" SE="1.189797902006491" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" WEIGHT="62.3317135598482"/>
<CONT_DATA CI_END="3.4997695390606247" CI_START="-2.4997695390606247" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="24.5" ORDER="259" SD_1="5.7" SD_2="7.2" SE="1.5305227865013968" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" WEIGHT="37.6682864401518"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.07" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES">
<NAME>Mental state: 3. Various scales (skewed endpoint data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_SUBGROUP ID="CMP-003.07.01" NO="1" STUDIES="2">
<NAME>general (BPRS, high = poor)</NAME>
<OTHER_DATA ORDER="27" STUDY_ID="STD-Eberhard-1986">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 7.3 SD 7.2. N=16.<BR/>2. Flupenthixol decanoate - mean 5.7 SD 7.2. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="28" STUDY_ID="STD-Wistedt-1991">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 8.5 SD 5.5. N=23.<BR/>2. Zuclopenthixol decanoate - mean 10.1 SD 7.0. N=33.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.07.02" NO="2" STUDIES="2">
<NAME>general (CPRS, high = poor)</NAME>
<OTHER_DATA ORDER="29" STUDY_ID="STD-Eberhard-1986">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 7.3 SD 7.2. N=16.<BR/>2. Flupenthixol decanoate - mean 5.7 SD 7.2. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="30" STUDY_ID="STD-Wistedt-1984">
<TR>
<TD>
<P>1. Haloperidol decanoate: mean 3, SD 2.5. N=25.<BR/>2. Fluphenazine decanoate: mean 4.1 SD 2.0. N=26.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.07.03" NO="3" STUDIES="1">
<NAME>general (Krawiecka scale, high = poor)</NAME>
<OTHER_DATA ORDER="31" STUDY_ID="STD-McKane-1987">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 8.5 SD 5.0. N=17.<BR/>2. Fluphenazine decanoate - mean 8.2 SD 5.4. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.07.04" NO="4" STUDIES="3">
<NAME>specific - depression</NAME>
<OTHER_DATA ORDER="32" STUDY_ID="STD-Eberhard-1986">
<TR>
<TD>
<P>CPRS - depression subscale, high = poor.<BR/>1. Haloperidol decanoate - mean 6.9 SD 6.0. N=16.<BR/>2. Flupenthixol decanoate - mean 6.8 SD 6.8. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="33" STUDY_ID="STD-Wistedt-1984">
<TR>
<TD>
<P>CPRS - depression subscale, high = poor.<BR/>1. Haloperidol decanoate - mean 0.9 SD 4.5. N=25.<BR/>2. Fluphenazine decanoate - mean 2.5 SD 2.6. N=26.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="34" STUDY_ID="STD-Wistedt-1991">
<TR>
<TD>
<P>MADRS, high = poor.<BR/>1. Haloperidol decanoate - mean 1.5 SD 2.7. N=23.<BR/>2. Zuclopenthixol decanoate - mean 1.1 SD 1.5. N=33.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="8.250098756805151" CI_END="1.6007874162341866" CI_START="0.5151107332991622" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9080654050411034" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="33" I2="15.152530819997745" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.20433366165918032" LOG_CI_START="-0.2880994006842943" LOG_EFFECT_SIZE="-0.041882869512556944" METHOD="PETO" NO="8" P_CHI2="0.3110582180012824" P_Q="1.0" P_Z="0.7388313695540882" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="184" WEIGHT="100.0" Z="0.33340131721921157">
<NAME>Behaviour: 1. Leaving the study early</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.284238322315434" CI_START="0.12353299588152161" EFFECT_SIZE="0.948600960715629" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.862384146399835" LOG_CI_START="-0.9082170260858925" LOG_EFFECT_SIZE="-0.022916439843028734" ORDER="268" O_E="-0.04878048780487809" SE="1.040059893335274" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" VAR="0.9244497323022011" WEIGHT="7.734868118748597"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="269" O_E="-0.5" SE="2.0" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" VAR="0.25" WEIGHT="2.091749245112032"/>
<DICH_DATA CI_END="130.0462090355012" CI_START="0.429832178234132" EFFECT_SIZE="7.476499535265201" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1140976966398526" LOG_CI_START="-0.3667010753350041" LOG_EFFECT_SIZE="0.8736983106524245" ORDER="270" O_E="0.9473684210526316" SE="1.457233478810004" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="3.9401370822054895"/>
<DICH_DATA CI_END="5.73975951757274" CI_START="0.17422332711647917" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7588936968615585" LOG_CI_START="-0.7588936968615584" LOG_EFFECT_SIZE="0.0" ORDER="271" O_E="0.0" SE="0.8915558282417286" STUDY_ID="STD-Eberhard-1986" TOTAL_1="16" TOTAL_2="16" VAR="1.2580645161290323" WEIGHT="10.526222007660548"/>
<DICH_DATA CI_END="0.9704528355095209" CI_START="0.11024062930320734" EFFECT_SIZE="0.32708306482551425" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="-0.013025566690556595" LOG_CI_START="-0.9576583162806954" LOG_EFFECT_SIZE="-0.4853419414856259" ORDER="272" O_E="-3.6296296296296298" SE="0.5548819531167717" STUDY_ID="STD-Kissling-1985" TOTAL_1="32" TOTAL_2="22" VAR="3.247871211532986" WEIGHT="27.1749286197809"/>
<DICH_DATA CI_END="4.473674357266631" CI_START="0.3432746004942435" EFFECT_SIZE="1.2392331409916555" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.6506643682297059" LOG_CI_START="-0.464358329616137" LOG_EFFECT_SIZE="0.09315301930678442" ORDER="273" O_E="0.5" SE="0.654969852166019" STUDY_ID="STD-McKane-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.331081081081081" WEIGHT="19.504148366585163"/>
<DICH_DATA CI_END="4.666284148900026" CI_START="0.2347747529804471" EFFECT_SIZE="1.0466736398680245" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6689711812091163" LOG_CI_START="-0.629348607725993" LOG_EFFECT_SIZE="0.01981128674156158" ORDER="274" O_E="0.07843137254901977" SE="0.7626394708070884" STUDY_ID="STD-Wistedt-1984" TOTAL_1="25" TOTAL_2="26" VAR="1.7193387158785083" WEIGHT="14.38570184412304"/>
<DICH_DATA CI_END="10.368126766168231" CI_START="0.5355555541358374" EFFECT_SIZE="2.3564184423836605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.015700298471618" LOG_CI_START="-0.27119547235175784" LOG_EFFECT_SIZE="0.3722524130599301" ORDER="275" O_E="1.5" SE="0.7559289460184544" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="1.75" WEIGHT="14.642244715784225"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.09" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Behaviour: 2. Wing Ward Behaviour Scale (skewed endpoint data, high=poor).</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="43" STUDY_ID="STD-McKane-1987">
<TR>
<TD>
<P>1. Haloperidol decanaote - mean 5.5 SD 4.1. N=17.<BR/>2. Fluphenazine decanoate - mean 4.8 SD 4.4. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="5.0630542645796375" CI_END="1.4389878655038253" CI_START="0.5681092009192983" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9041583082646228" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="102" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.158057131694111" LOG_CI_START="-0.24556817696790725" LOG_EFFECT_SIZE="-0.04375552263689816" METHOD="PETO" NO="10" P_CHI2="0.652268698124211" P_Q="0.6607287103190822" P_Z="0.6708768784870174" Q="0.8288239382109701" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="194" TOTAL_2="209" WEIGHT="300.0" Z="0.42494485183464653">
<NAME>Side effects: 1. Movement disorders</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03579945439239435" CI_END="3.060943671044938" CI_START="0.5310403436847477" DF="1.0" EFFECT_SIZE="1.2749449317799404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.4858553375753004" LOG_CI_START="-0.2748724838637231" LOG_EFFECT_SIZE="0.10549142685578863" NO="1" P_CHI2="0.8499303037504301" P_Z="0.5867283878447391" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="56" WEIGHT="100.0" Z="0.5435831094594984">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="4.263171216069749" CI_START="0.3167485619230962" EFFECT_SIZE="1.1620470523700968" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.629732774988467" LOG_CI_START="-0.499285348189688" LOG_EFFECT_SIZE="0.06522371339938955" ORDER="277" O_E="0.34146341463414664" SE="0.6631908342846918" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" VAR="2.2736466389054133" WEIGHT="45.40009614260287"/>
<DICH_DATA CI_END="4.505391574469425" CI_START="0.4209358605035989" EFFECT_SIZE="1.377127764335957" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.6537325425383911" LOG_CI_START="-0.3757840741203098" LOG_EFFECT_SIZE="0.13897423420904054" ORDER="278" O_E="0.875" SE="0.6047431568147635" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="2.734375" WEIGHT="54.59990385739714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.198430871976273" CI_END="1.4737204345355632" CI_START="0.4327495668849268" DF="4.0" EFFECT_SIZE="0.7985936887771723" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="80" I2="4.726310329431906" ID="CMP-003.10.02" LOG_CI_END="0.16841510546744967" LOG_CI_START="-0.36376335811364413" LOG_EFFECT_SIZE="-0.0976741263230972" NO="2" P_CHI2="0.37981677900840294" P_Z="0.47186400061098344" STUDIES="5" TAU2="0.0" TOTAL_1="124" TOTAL_2="133" WEIGHT="100.0" Z="0.7194495189695506">
<NAME>needing anticholinergic drugs</NAME>
<DICH_DATA CI_END="2.566756957856919" CI_START="0.09282988519426405" EFFECT_SIZE="0.4881308776541761" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.4093847479629426" LOG_CI_START="-1.0323121866524554" LOG_EFFECT_SIZE="-0.31146371934475636" ORDER="279" O_E="-1.0" SE="0.8468599159080074" STUDY_ID="STD-Chouinard-1984" TOTAL_1="36" TOTAL_2="36" VAR="1.3943661971830985" WEIGHT="13.625945282980712"/>
<DICH_DATA CI_END="6.150144771113853" CI_START="0.2959863900918002" EFFECT_SIZE="1.349206859359954" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7888853389552343" LOG_CI_START="-0.5287282580083588" LOG_EFFECT_SIZE="0.1300785404734378" ORDER="280" O_E="0.5" SE="0.7739727491489096" STUDY_ID="STD-Eberhard-1986" TOTAL_1="16" TOTAL_2="16" VAR="1.6693548387096773" WEIGHT="16.31317349494685"/>
<DICH_DATA CI_END="7.096838490814296" CI_START="0.2786993289938695" EFFECT_SIZE="1.4063726836680988" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.8510649217082062" LOG_CI_START="-0.5548640769078318" LOG_EFFECT_SIZE="0.14810042240018725" ORDER="281" O_E="0.5" SE="0.8258496532478447" STUDY_ID="STD-McKane-1987" TOTAL_1="19" TOTAL_2="19" VAR="1.4662162162162165" WEIGHT="14.328073913109737"/>
<DICH_DATA CI_END="1.0699105768372872" CI_START="0.10998236856690456" EFFECT_SIZE="0.34303250486702863" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.029347480854338776" LOG_CI_START="-0.9586769316403182" LOG_EFFECT_SIZE="-0.46466472539298964" ORDER="282" O_E="-3.1764705882352935" SE="0.5803704306990811" STUDY_ID="STD-Wistedt-1984" TOTAL_1="25" TOTAL_2="26" VAR="2.968858131487889" WEIGHT="29.012104950844744"/>
<DICH_DATA CI_END="4.505391574469425" CI_START="0.4209358605035989" EFFECT_SIZE="1.377127764335957" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.6537325425383911" LOG_CI_START="-0.3757840741203098" LOG_EFFECT_SIZE="0.13897423420904054" ORDER="283" O_E="0.875" SE="0.6047431568147635" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="2.734375" WEIGHT="26.720702358117954"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.586221530891966" CI_START="0.22195366296189323" DF="0.0" EFFECT_SIZE="0.7576419616232901" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="0.4126657229895668" LOG_CI_START="-0.6537376832990749" LOG_EFFECT_SIZE="-0.120535980154754" NO="3" P_CHI2="1.0" P_Z="0.6577144249667172" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0" Z="0.4430709402303021">
<NAME>tremor</NAME>
<DICH_DATA CI_END="2.586221530891967" CI_START="0.22195366296189317" EFFECT_SIZE="0.7576419616232901" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.41266572298956694" LOG_CI_START="-0.6537376832990749" LOG_EFFECT_SIZE="-0.120535980154754" ORDER="284" O_E="-0.7073170731707314" SE="0.6264106396359445" STUDY_ID="STD-Bechelli-1985" TOTAL_1="21" TOTAL_2="20" VAR="2.5484830458060674" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.11" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Side effects: 2. Movement disorders - various scales (skewed endpoint data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_SUBGROUP ID="CMP-003.11.01" NO="1" STUDIES="2">
<NAME>parkinsonism (Simpson &amp; Angus scale, high = poor)</NAME>
<OTHER_DATA ORDER="52" STUDY_ID="STD-McKane-1987">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 3.5 SD 3.2. N=17.<BR/>2. Fluphenazine decanoate - mean 4.0 SD 3.0. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="53" STUDY_ID="STD-Wistedt-1984">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 2.7 SD 6.0. N=25.<BR/>2. Fluphenazine decanoate - mean 2.3 SD 8.2. N=26.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.02" NO="2" STUDIES="1">
<NAME>tardive dyskinesia (AIMS, high = poor)</NAME>
<OTHER_DATA ORDER="54" STUDY_ID="STD-McKane-1987">
<TR>
<TD>
<P>1. Haloperidol decanoate - mean 4.6 SD 5.1. N=17.<BR/>2. Fluphenazine decanoate- mean 2.9 SD 2.9. N=16.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8602940277109248" CI_START="0.2617966700402792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6978673095585857" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.26958159180958297" LOG_CI_START="-0.5820358818201337" LOG_EFFECT_SIZE="-0.1562271450052754" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.47207856754355026" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="36" WEIGHT="100.0" Z="0.7191012094028308">
<NAME>Side effects: 3. Significant side effects reported</NAME>
<GROUP_LABEL_1>Haldol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8602940277109248" CI_START="0.2617966700402792" EFFECT_SIZE="0.6978673095585857" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.26958159180958297" LOG_CI_START="-0.5820358818201337" LOG_EFFECT_SIZE="-0.1562271450052754" ORDER="288" O_E="-1.4375" SE="0.5002443195845779" STUDY_ID="STD-Wistedt-1991" TOTAL_1="28" TOTAL_2="36" VAR="3.99609375" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>General comment</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The review is hard to read and assimilate. One problem is that the typographical distinctions between different levels of heading and subheading are insufficient. The editorial team rather than the reviewers need to address this.</P>
<P>1. Category: Abstract<BR/>The abstract does not state the number of included trials.</P>
<P>2. Category: Objectives<BR/>This could be improved by adding the comparisons examined in the review. </P>
<P>3. Category: Results<BR/>The number of trials and number of participants contributing to each comparison is missing.</P>
<P>4. Category: Included studies table<BR/>The standard alphabetical arrangement of trials by author's name makes it laborious to separate the various comparisons. It would be better to group them according to comparisons they make.</P>
<P>5. Category: Acknowledgements<BR/>It is a surprise to see the authors acknowledging their own contributions!<BR/>Presumably this is just a problem of syntax - conflating a statement of what each author contributed to the review with an acknowledgement to others who were not authors.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>The Cochrane Library is evolving and such comments help to improve the readability of the reviews and as such will be addressed by the editorial body. </P>
<P>1. Category: Abstract<BR/>This information is now included.</P>
<P>2. Category: Objectives<BR/>This omission will be rectified in the next update. </P>
<P>3. Category: Results<BR/>The data will be included in the next update.</P>
<P>4. Category: Included studies table<BR/>The included studies table will be amended in the update.</P>
<P>5. Category: Acknowledgements<BR/>Reviews in the Cochrane Library, formatted in RevMan 4.0.4 are now using contributorship, making explicit the input of each author. The Cochrane Schizophrenia Group instigated this policy when RevMan 3.1 was being used and as there was no obvious place to cite the contributions of each author it was put into the area dedicated to acknowledgements.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment received from Andrew Herxheimer, London, March 1999.<BR/>Reply from Seema Quraishi, London, December 1999.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>